Lill-Brith von Arx

@t_kjaer @SallyStearns1 Congratulations @t_kjaer!

Excited and honoured to become an Associate Editor of Health Economics! Thanks to @SallyStearns1 and editorial team for the invitation. onlinelibrary.wiley.com/journal/109910…

Seasons Greetings linkedin.com/pulse/seasons-…

To gode nyheder! Sundhedsøkonom i Medicinrådet og det er @DorteGyrd. Stort tillykke til dig, Dorte

Inequality in Health. ApHER research referenced at #danskekræftforskningsdage by Astrid Nørgaard, Danish Health & Authority. Read the full report on cancer survival here: dmcg.dk/siteassets/ars…

Lægemiddelindustrien: Vi kan ikke nøjes med at forske i eksisterende lægemidler altinget.dk/sundhed/artike…

Multiple Sclerosis in Denmark. Inadequate and unequal access to neurological expertise and rehabilitation. Professor Anders Green and ApEHR at MS Political Meeting, Industriens Hus, Copenhagen, 20. March 2018 #mstopmødet2018

@DorteGyrd The best of both worlds: New @COHERE_SDU pub linking survey and register data. Thanks to @DorteGyrd and @mr_moerkbak for great collaboration

Insight on early onset diabetes through behavioral economics. Empirical data on why individuals putting off action (…lnkd.in/g-SmQWR

Insight on early onset diabetes through behavioral economics. Empirical data on why individuals putting off action (…lnkd.in/gNHgCxf

FDA hosting workshop on diabetes outcomes beyond HbA1c, August 29. Novo Nordisk is represented. fda.gov/Drugs/NewsEven…

@gertwbos thank you so much for your answer. Personal liability is a topic we have discussed with our QPPV collegues.

@gertwbos At the recent webinar you mentioned that QP drug concept didn't quit make it. Could you please enlarge on this? Txs

Congrats to @lillvon (@COHERE_SDU) who was awarded the PhD degree today! Thesis: "Individual‐Level Perspectives in Drug Development..."

"What are predictors of diabetes outcome - beliefs or actions?" on @LinkedIn linkedin.com/pulse/what-pre…